Legal & General Group
CADL icon

Legal & General Group’s Candel Therapeutics CADL Stock Holding History

Legal & General Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.3K Buy
6,148
+2,567
+72% +$19.4K ﹤0.01% 2707
2026
Q1 		$17.5K Sell
3,581
-650
-15% -$3.54K ﹤0.01% 3009
2025
Q4 		$23.9K Hold
4,231
– – ﹤0.01% 2956
2025
Q3 		$21.6K Sell
4,231
-156
-4% -$901 ﹤0.01% 3006
2025
Q2 		$22.2K Buy
4,387
+1,288
+42% +$6.63K ﹤0.01% 2965
2025
Q1 		$17.5K Buy
3,099
+902
+41% +$7.37K ﹤0.01% 2984
2024
Q4 		$19.1K Hold
2,197
– – ﹤0.01% 3041
2024
Q3 		$15.2K Hold
2,197
– – ﹤0.01% 3155
2024
Q2 		$13.6K Buy
+2,197
New +$16.5K ﹤0.01% 3194

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Legal & General Group's CADL Position: Q2 2026 in Review

Legal & General Group increased its Candel Therapeutics (CADL) stake by 72% in Q2 2026, buying an estimated $19.4K and bringing the position to 6,148 shares worth $63.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2707.

Legal & General Group first reported a position in CADL in Q2 2024 and has held it in 9 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Legal & General Group held 6,148 shares of Candel Therapeutics worth $63.3K as of Q2 2026.
  • Legal & General Group bought 2,567 Candel Therapeutics shares in Q2 2026, an estimated $19.4K.
  • Candel Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2707 holding.
  • Legal & General Group first reported a position in Candel Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.